A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
A phase 1/2 trial of Datopotamab deruxtecan in non-small-cell lung cancer and triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) is a phase 1/2 interventional study registered as NCT05460273 by AstraZeneca, with 119 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2023-11-07. Interventions recorded: Datopotamab Deruxtecan (Dato-DXd). Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Datopotamab deruxtecan, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Shares Datopotamab deruxtecan, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialCapivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Shares AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.